A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus

Trial Profile

A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Riboflavin (Primary)
  • Indications Keratoconus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Avedro
  • Most Recent Events

    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2016 Planned End Date changed from 1 Jul 2016 to 1 Mar 2017.
    • 18 Apr 2016 According to an Avedro media release, based on the data from this and other two trials (see CTP 700245661 and 700238499) the company has received an approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top